Heron Therapeutics v. Azurity Pharmaceuticals: Defendant Wins After Bench Trial
Heron Therapeutics filed suit in the Delaware District Court alleging infringement of two aprepitant injectable emulsion patents via Azurity's NDA No. 218754. After a bench trial in November 2025, Judge Bryson declared the asserted claims of both patents invalid for lack of written description — a complete win for the defendant across all patent claims at issue.
Aprepitant Patent Claims Invalidated After Delaware Bench Trial
Heron Therapeutics, Inc. filed this patent infringement action in the Delaware District Court on December 12, 2024, asserting that Azurity Pharmaceuticals India LLP (formerly Slayback Pharma India LLP) and related entities infringed U.S. Patent Nos. 12,115,255 and 12,290,520 by filing NDA No. 218754 for a 130mg/18mL aprepitant injectable emulsion — the same formulation commercialized by Heron as Cinvanti®. The case proceeded to a bench trial before Judge William C. Bryson during the week of November 17, 2025, focusing on whether claims 5 and 23 of the '255 patent and claim 8 of the '520 patent were invalid for lack of written description and/or enablement under 35 U.S.C. § 112.
On June 1, 2026, the Court issued its findings of fact and conclusions of law and entered final judgment. The Court declared claims 5 and 23 of the '255 patent and claim 8 of the '520 patent invalid on the ground of lack of written description under 35 U.S.C. § 112. Judgment was granted in favor of Defendants on all of Heron's infringement claims. All other claims and counterclaims were dismissed without prejudice as moot, subject to reinstatement upon reversal or remand. Defendants were ordered to submit a copy of the Final Judgment to the FDA within 14 days pursuant to 21 C.F.R. § 314.107(e).
The case resolved in approximately 536 days — a relatively compact timeline for a pharmaceutical patent bench trial involving complex § 112 validity questions. The written description invalidity finding is a substantive merits outcome that, if not appealed or if affirmed on appeal, would clear a significant regulatory pathway obstacle for Azurity's NDA product. The judgment expressly contemplates appeal, with attorney fee motion deadlines tied to appellate timing. Whether Heron will appeal and whether any fee or cost motions will follow are not disclosed in the available record.
See Complete Case & Patent Analysis →Filing to Judgment on the merits for Defendant in 536 days
536 days from filing to final judgment — resolved within approximately 18 months
US12115255B2 & US12290520B2 — Aprepitant Injectable Emulsion Formulations
Any company developing, formulating, or seeking regulatory approval for an aprepitant injectable emulsion — particularly at a 130mg/18mL concentration — should conduct a freedom-to-operate analysis against Heron's aprepitant patent family. While claims 5 and 23 of the '255 patent and claim 8 of the '520 patent have been declared invalid, Heron's portfolio includes additional patents such as US12115254B2 whose enforceability in this context is not fully resolved by the present judgment. An appeal of this ruling could also reinstate the invalidated claims.
Official order — verbatim text
The Final Judgment declares claims 5 and 23 of U.S. Patent No. 12,115,255 and claim 8 of U.S. Patent No. 12,290,520 invalid for lack of written description under 35 U.S.C. § 112, following a full bench trial on the merits. The ruling grants judgment to Defendants on all of Heron's infringement claims and dismisses remaining claims without prejudice as moot — preserving Heron's ability to reinstate them if the judgment is reversed or remanded on appeal. The express FDA notification requirement and the structured attorney fee timing provisions embedded in the order reflect the regulatory and commercial stakes typical of NDA-linked pharmaceutical patent disputes.
Defendant judgment: what the bench trial ruling means for both parties
Written description invalidity under 35 U.S.C. § 112 explained
The Court found that claims 5 and 23 of the '255 patent and claim 8 of the '520 patent lack adequate written description under 35 U.S.C. § 112. This means the patent specifications, as filed, did not sufficiently describe the full scope of what was claimed, rendering those claims invalid as a matter of law. The ruling was made on the merits following a full bench trial, not on procedural grounds.
Merits — § 112 invalidityHeron loses enforceability of asserted Cinvanti® patent claims
The invalidity finding means Heron cannot enforce claims 5 and 23 of the '255 patent or claim 8 of the '520 patent against Azurity's NDA product in this action. All infringement claims have been resolved against Heron. Heron retains the right to appeal, and the judgment expressly preserves the ability to reinstate dismissed claims upon reversal or remand. Cost and attorney fee motions remain available within defined post-judgment windows.
Plaintiff — judgment againstAzurity clears a key patent barrier to its NDA aprepitant product
Judgment in favor of Defendants on all infringement claims means Azurity's NDA No. 218754 for 130mg/18mL aprepitant injectable emulsion is no longer blocked by these patent claims, subject to any appeal outcome. The Court ordered Defendants to notify the FDA of the Final Judgment within 14 days per 21 C.F.R. § 314.107(e), a step relevant to regulatory approval timing. The commercial significance depends on the broader NDA approval status, which is not disclosed in the available record.
Defendant — judgment in favorWritten description risk is a live threat for pharma NDA patent coverage
This outcome signals that pharmaceutical patent claims protecting injectable formulations remain vulnerable to written description challenges at bench trial, even when the commercial product is established. Companies filing or defending NDAs in competitive oncology-supportive care markets should assess whether their patent claims are fully supported by the specification. The FDA notification requirement also illustrates how patent judgments directly interact with regulatory approval timelines in Hatch-Waxman-adjacent disputes.
Pharma formulation — § 112 riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Heron Therapeutics, Inc. | Company | /Search in Eureka ↗ |
| Defendant | Azurity Pharmaceuticals India LLP | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for Heron Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Sydney Bruns | Attorney | Counsel for Heron Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Vladimir J. Semendyai | Attorney | Counsel for Heron Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Heron Therapeutics, Inc.Search in Eureka ↗ |
| Defendant counsel | Barnaby Grzaslewicz | Attorney | Counsel for Azurity Pharmaceuticals India LLPSearch in Eureka ↗ |
| Defendant counsel | Cortlan S. Hitch | Attorney | Counsel for Azurity Pharmaceuticals India LLPSearch in Eureka ↗ |
| Defendant counsel | Elham F. Steiner | Attorney | Counsel for Azurity Pharmaceuticals India LLPSearch in Eureka ↗ |
| Defendant counsel | Joanna Garelick Goldstein | Attorney | Counsel for Azurity Pharmaceuticals India LLPSearch in Eureka ↗ |
| Defendant counsel | Kenneth Laurence Dorsney | Attorney | Counsel for Azurity Pharmaceuticals India LLPSearch in Eureka ↗ |
| Defendant counsel | Robyn H. Ast-Gmoser | Attorney | Counsel for Azurity Pharmaceuticals India LLPSearch in Eureka ↗ |
| Defendant law firm | Morris James LLP | Law Firm | Representing Azurity Pharmaceuticals India LLPSearch in Eureka ↗ |
| Presiding judge | Judge William C. Bryson | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the aprepitant injectable formulation IP space
Forward-looking patent intelligence signals for R&D and IP teams active in injectable antiemetic formulations and oncology-supportive care — drawn from the Heron v. Azurity dispute.
Heron's aprepitant patent family: depth and vulnerability
Heron's NDA-linked patents for Cinvanti® include at least three US patents (US12115254B2, US12115255B2, US12290520B2) from a cluster of continuation applications. The written description invalidity of specific claims in two of these patents suggests the family may have variable claim-level support. Examining the remaining claims and any pending continuations is a priority intelligence task for competitors and NDA challengers.
Heron aprepitant portfolioFiling trends in injectable antiemetic emulsion formulations
Aprepitant injectable emulsions sit at the intersection of oncology supportive care and specialty pharmaceutical formulation. Patent filing activity in lipid-based injectable drug delivery — including emulsifiers, stabilizers, and concentration optimization — has grown alongside clinical adoption of NK-1 antagonists. Monitoring claim strategies in this space can reveal where the next NDA-linked patent barriers are being constructed.
Injectable emulsion filing trendsAzurity's IP position in specialty injectable generics
Azurity Pharmaceuticals (including its Indian entity, formerly Slayback Pharma India LLP) is active in specialty pharmaceutical formulations. Understanding Azurity's own patent filings — including any defensive IP around its NDA product — provides intelligence on how this company protects its generic and specialty portfolio and where future IP conflicts may arise in the injectable formulation space.
Azurity patent activitySpecification-supported formulation claims: a gap in the market
The Court's written description ruling signals that broad formulation claims in injectable emulsions are vulnerable when specification disclosure is thin. R&D teams can exploit this white space by building robust, experimentally grounded patent specifications for novel antiemetic or oncology-supportive injectable formulations — establishing stronger § 112 foundations than those found insufficient in the '255 and '520 patents.
§ 112 white space strategySimilar pharmaceutical formulation patent cases in Delaware District Court
Explore comparable NDA-linked pharmaceutical formulation patent bench trials in the Delaware District Court, including § 112 written description challenges against injectable drug patents.
What this case signals for the pharmaceutical formulation IP landscape
A bench trial invalidity win in Delaware on § 112 grounds carries real weight for branded pharma patentees and NDA challengers alike.
Written description is a viable invalidity path for injectable formulation patents
This outcome demonstrates that § 112 written description challenges can succeed at bench trial against pharmaceutical formulation patents, including those protecting established commercial products. Companies holding NDA-linked patents should audit claims for specification support, particularly for claims with broad functional or compositional scope.
FDA notification orders mean patent judgments have immediate regulatory consequences
The Court's order requiring Azurity to notify the FDA within 14 days of the judgment — per 21 C.F.R. § 314.107(e) — illustrates how patent trial outcomes directly influence NDA regulatory timelines. IP teams involved in pharmaceutical litigation should coordinate closely with regulatory affairs functions when bench trial rulings are entered.
Heron v Azurity — key questions answered
The Delaware District Court entered judgment in favor of Defendants on June 1, 2026, after a bench trial. Claims 5 and 23 of U.S. Patent No. 12,115,255 and claim 8 of U.S. Patent No. 12,290,520 were declared invalid for lack of written description under 35 U.S.C. § 112. All of Heron's infringement claims were dismissed in favor of Defendants.
The Court found that the asserted claims lacked adequate written description under 35 U.S.C. § 112. This means the patent specifications did not sufficiently describe the full scope of what was claimed. The ruling was made on the merits following a bench trial held the week of November 17, 2025.
The case primarily addressed U.S. Patent Nos. 12,115,255 and 12,290,520, covering aprepitant injectable emulsion formulations underlying Heron's Cinvanti® product. U.S. Patent No. 12,115,254 is also listed among the patents involved, though the specific adjudicated claims in the verdict relate to the '255 and '520 patents.
The Court ordered Defendants to submit a copy of the Final Judgment to the FDA within 14 days of entry, pursuant to 21 C.F.R. § 314.107(e). This provision is relevant to the regulatory approval timeline for Azurity's NDA No. 218754, as patent judgment outcomes can affect the FDA's determination of when a drug may receive final approval.
The Final Judgment contemplates appeal, with attorney fee and cost motion deadlines expressly tied to appellate timing under Fed. R. App. P. 3 and 4. The judgment also provides for reinstatement of dismissed claims upon reversal or remand. Whether Heron has filed or will file a notice of appeal is not disclosed in the available record.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.